Diagnostyka FY25 revenue tops estimates on strong growth

Diagnostyka reported FY2025 revenue of PLN 2.41bn, up 23.6% year over year and slightly ahead of consensus and guidance, but adjusted EBITDA of PLN 586.4m missed estimates by 5% as margin compressed to 24.3% from 26.1%. Net profit came in at PLN 251.6m, 8.2% below consensus, while capex of about PLN 205m exceeded the guided PLN 130m-170m range. Management kept FY2026 guidance constructive, calling for low-to-mid teens revenue growth and an EBITDA margin near 24.3%, alongside a proposed dividend of PLN 4.4 per share.

Analysis

The headline risk is not the revenue miss-or-beat; it is the implied reset in operating leverage. When pricing is doing most of the heavy lifting while volumes slow and wage inflation is sticky, the next 2-3 quarters likely feature margin compression unless management can re-accelerate throughput or pass through costs faster than peers. That makes the company’s near-term earnings power more sensitive to mix and labor than the top-line print suggests, which is exactly the kind of dynamic that tends to catch quality-growth investors off guard.

Second-order, the regulatory wage change effectively narrows the gap between the best-run operator and the rest of the market. If all providers face higher labor costs, the winners are those with denser utilization, better procurement, and more automation; smaller regional competitors may be forced to raise prices more aggressively or sacrifice service levels. That can preserve the industry’s pricing umbrella over time, but in the short run it also raises the risk that volume elasticity worsens as end-demand absorbs the higher sticker price.

The cash-flow story is still the key contrarian point. Strong conversion despite elevated capex suggests the business can fund dividends and incremental expansion without stressing the balance sheet, which should put a floor under the stock on drawdowns. But if capex normalizes and margins stay at the new level instead of recovering, the market will likely re-rate the name from an earnings-growth compounder to a slower, utility-like cash generator.

For us, the setup is less about chasing the stock and more about timing around management commentary. If the call confirms margin stabilization and capex moderation, the market may reward the dividend support and treat the guide-down as a one-off cost shock; if not, the next leg down could be driven by multiple compression rather than earnings downgrades alone.

Key Decisions for Investors

• Avoid initiating a fresh long until after the earnings call; use the next 1-2 weeks to see whether management credibly explains margin bridge and capex normalization. Risk/reward is poor if the market starts pricing this as a permanently lower-margin business.
• If already long, consider trimming 25-50% into any post-call strength and retain the rest only if management signals FY26 margin floor and no further capex surprise. The stock’s upside likely comes from multiple support, not near-term EPS momentum.
• Pair trade: long a higher-quality, labor-light diagnostics/platform name versus short DIAP into the next 1-3 months if you expect wage pressure to keep margin dispersion wide. The thesis is that the market is underestimating how much of current profitability is cost-cycle-dependent.
• Sell downside protection via put spread instead of outright short if liquidity is decent and dividend support is meaningful. This captures the possibility that the market overreacted to a transitory cost shock while limiting exposure if pricing power proves weaker than expected.
• Watch for a 1H26 rerating opportunity only if utilization and volume growth re-accelerate; absent that, treat the name as a cash-yield hold rather than a growth compounder. The best entry would be after a second print confirming the margin reset is stable, not immediately after the headline.